IMab Acquires China Rights to IO mAb from MorphoSys in $105 Million Deal

I-Mab Acquires China Rights to I-O mAb from MorphoSys in $105 Million Deal

I-Mab Biopharma of Tianjin in-licensed greater China rights to a novel checkpoint inhibitor from Germany's MorphoSys in a $105 million agreement. I-Mab will also conduct proof-of-concept clinical studies of MOR210, a preclinical C5aR antibody. In return for the proof-of-concept studies, MorphoSys will pay I-Mab single digit royalties on any revenues outside greater China. One year ago, I-Mab in-licensed rights to a MorphoSys anti-CD38 mAb in a $120 million deal. More details....

Stock Symbols:  (FSE/NSDQ: MOR)

Share this with colleagues:

More From BioPortfolio on "I-Mab Acquires China Rights to I-O mAb from MorphoSys in $105 Million Deal"